StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Equities researchers at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS opened at $0.03 on Wednesday. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.78. The business has a 50 day moving average price of $0.03 and a two-hundred day moving average price of $0.04. The company has a market cap of $1.28 million, a PE ratio of 0.00 and a beta of 1.68.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.